225Ac-HER3 ARC,177lu-her3 arc
actinium,novartis
['177lu-her3 arc', '225ac', 'solid tumor']
today from 1:30 pm 5:00 pm et at #aacr23, our second poster will be available. novel her3 targeting antibody radioconjugates, 225ac-her3 arc and 177lu-her3 arc, exhibit potent antitumor efficacy in her3-positive solid tumors in section 19. 
Actinium is developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently investigating therapies in #AML #BMT $ATNM